In addition to our current blogs (www.biosimilarsrr.com), here is a sampling of recent publications and articles developed by SM Health Communications LLC:

• Mehr SR: The US Biosimilar Market: A History of Growth and Towards a Sustainable Future. Ed 3. SM Health Communications. January 2023. https://biosimilarsrr.com/our-biosimilars-market-report/
• Rett Syndrome. CheckRare February 6, 2023. https://checkrare.com/rett-syndrome/ (uncredited)
• Recognizing and Diagnosing WHIM Syndrome. CheckRare January 12, 2023. https://checkrare.com/recognizing-and-diagnosing-whim-syndrome/ (uncredited)
• Current Trends and Changes Impacting Biosimilars. Presentation given at 2022 Informa Biosimilar and Biologics, Specialty Drug Congress. December 13, 2022, Philadelphia.
• Type 1 Galactosemia: Significant Unmet Need, Lifelong Complications, and Current Management. CheckRare March 30, 2022. https://checkrare.com/galactosemia-disease-resource-center/ (uncredited)
• The Biosimilar Pipeline Post-Adalimumab: 2024-2027. Presentation given at the 2022 World Biosimilar Congress (Festival of Biologics), March 10, 2022, San Diego.
• Mehr SR: Where the US Biosimilars Market Is Heading and When It Might Get There. Ed 2. SM Health Communications January 2021. https://biosimilarsrr.com/our-biosimilars-market-report/.
• Niemann-Pick Disease Type C. CheckRare November 17, 2020. https://checkrare.com/niemann-pick-disease-type-c/. (uncredited)
• Angelman Syndrome. CheckRare November 17, 2020. https://checkrare.com/angelman-syndrome/ (uncredited)
• Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. CheckRare November 17, 2020. https://checkrare.com/aromatic-l-amino-acid-decarboxylase-aadc-deficiency/. (uncredited)
• Mehr SR: Which Biosimilar Companies Will Thrive in 2025? Biosimilar Development March 31, 2020. https://www.biosimilardevelopment.com/doc/which-biosimilar-companies-will-thrive-in-0001.
• Mehr SR: Where the US Biosimilars Market Is Heading and When It Might Get There. Ed 1. SM Health Communications February 2020. https://biosimilarsrr.com/our-biosimilars-market-report/.
• Mehr SR, Brook RA:  Biosimilars in the USA: Will new efforts to spur approvals and access spur uptake and cost savings? Pharmaceutical Medicine 2019; https://doi.org/10.1007/s40290-018-00262-z.
• Mehr SR: Can the FTC Clear a Path for Biosimilar Access Through the Patent Thicket? Biosimilar Development June 4, 2019. https://www.biosimilardevelopment.com/doc/can-the-ftc-clear-a-path-for-biosimilar-access-through-the-patent-thicket-0001.
• Medicare’s International Pricing Index–Biosimilar Stakeholders Weigh In. Biosimilar Development February 19, 2019. https://www.biosimilardevelopment.com/doc/medicare-s-international-pricing-index-biosimilar-stakeholders-weigh-in-0001.
• Mehr SR: If four-letter suffixes aren’t used in biosimilar tracking, what use are they? Biosimilar Development. November 6, 2018. https://www.biosimilardevelopment.com/doc/if-four-letter-suffixes-aren-t-used-in-biosimilar-tracking-what-use-are-they-0001.
• Mehr SR, Renfro M: The Patient’s Paramount Place: Emphasis on Empowerment, Engagement, Experience. Academy of Managed Care Pharmacy Foundation. August 2018. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=23845.
• Mehr SR, Reinert A: The Rx affordability crisis. Academy of Managed Care Pharmacy Foundation. September 2017. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=22747
• Mehr SR, Brook RA: Factors influencing the economics of biosimilars in the US. J Med Econ 2017;20(12):1268-1271. doi:10.1080/13696998.2017.1366325.
• Mehr SR: Pharmaceutical patent litigation and the emerging biosimilars: A conversation with Kevin M. Nelson, JD. Am Health Drug Benefits. 2017;10(1):23-26.
• Mehr SR: Maximizing Value in Health Care. Academy of Managed Care Pharmacy Foundation. June 2017 http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=22527.
• Mehr SR, Zimmerman MP: Is a biologic produced 15 years ago a biosimilar of itself today? Am Health Drug Benefits. 2016;9(9):515-518.
• Mehr SR: Will the PCSK9 inhibitors be employers’ “line in the sand”? Am Health Drug Benefits 2016;9(3):171-174.
• Mehr SR: Payer perspectives on PCSK9 inhibitors: A conversation with Stephen Gorshow, MD, and James T. Kenney, RPh, MBA. Am Health Drug Benefits. 2016;9(1):38-41.
• Mehr SR: AMCP Market Insights: Focus on Psoriasis. American Medical Communications, Manalpan, NJ, June 2016.
• Mehr SR: Ahead of the curve: Emerging trends implications for policy-makers and patients. Academy of Managed Care Pharmacy Foundation. September 2016. http://www.amcp.org/ET_Whitepaper/.
• Mehr SR: The Top 5 Health Benefits/Delivery Trends Affecting Oncology Business Practices. Oncology Practice Management 2016;2(6). (http://oncpracticemanagement.com/issue-archive/special-issues/innovations-oncology-management-vol-2-no-6/top-5-health-benefits-delivery-trends-affecting-oncology-business-practices/)
• Opportunities and Challenges in Patient Care, Prevention, and Adherence. AMCP Foundation, http://www.amcp.org/2015_SymposiumSummary/. October 26, 2015.
• Mehr SR, Zimmerman MP: Reviewing the Unmet Needs in Multiple Sclerosis. Am Health Drug Benefits. 2015;8(8):426-431.

• Emerging Trends: Series of 3 Webinars for the Academy of Managed Care Pharmacy Foundation. 2015. (www.amcp.org)
• Radick L, Mehr SR: The Latest Innovations and the Phase 3 Pipeline for Multiple Sclerosis. Am Health Drug Benefits 2015;8(8):448-453.
• Mehr SR: The Payer Perspective: An Interview With Stephen Gorshow, MD, and James Kenney, RPh, MBA. Am Health Drug Benefits 2016;9(1):38-41.
• Mehr SR: Will the PCSK9 Inhibitors Be Employers’ “Line in the Sand?” Am Health Drug Benefits. 2016;9(3):171-174 .
• Specialty Pharmacy and Patient Care: Are We at a Tipping Point?  AMCP Foundation, http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=18858 October 7, 2014.
• AMCP Task Force on Biosimilar Collective Intelligence Systems Utilizing Data Consortia to Monitor Safety and Effectiveness of Biosimilars and Their Innovator Products. J Manag Care Pharm 2015;21(1):23-34.
• Mehr SR: The Intestinal Bug Hypothesis in Crohn’s Disease Gets a Reboot. Am J Manag Care (Evidence-Based Inflammatory and Infectious Disease) http://www.ajmc.com/publications/ebiid/2014/october-2014#sthash.y8t2JTJY.dpuf. October 21, 2014.
• Mehr SR: The Economic Costs of Crohn’s Disease. Am J Manag Care (Evidence-Based Inflammatory and Infectious Disease http://www.ajmc.com/publications/ebiid/2014/october-2014/The-Economic-Costs-of-Crohns-Disease. October 21, 2014.
• Zimmerman MP, Mehr SR: Recurrence of Breast Cancer Years After the Initial Tumor. Am J Manag Care (Evidence-Based Oncology) http://www.ajmc.com/publications/evidence-based-oncology/2014/september-2014/Recurrence-of-Breast-Cancer-Years-After-the-Initial-Tumor#sthash.ppJA6MC9.dpuf. September 14, 2014
• Zimmerman MP, Mehr SR: Breast Cancer Survivorship Programs: More Than a Treatment. Am J Manag Care (Evidence-Based Oncology) http://www.ajmc.com/publications/evidence-based-oncology/2014/september-2014/Breast-Cancer-Survivorship-Programs-More-Than-a-Treatment#sthash.6pG7kpEq.dpuf. September 14, 2014.
• Mehr SR, Caffrey MK: Exploring the Intersection of Chronic Disease, Adherence, and Life Expectancy. Am J Manag Care (Evidence-Based Diabetes Care) http://www.ajmc.com/publications/evidence-based-diabetes-management/2014/september-october-2014/Exploring-the-Intersection-of-Chronic-Disease-Adherence-and-Life-Expectancy#sthash.fVHrEOl0.dpuf. October 14, 2014.
• Mehr SR: Upending of Conventional Combination Therapy in Type 2 Diabetes Mellitus. Am J Manag Care (Evidence-Based Diabetes Care) www.ajmc.com/publications/evidence-based-diabetes-management/2014/september-october-2014/Upending-of-Conventional-Combination-Therapy-in-Type-2-Diabetes-Mellitus#sthash.3KxIpko7.dpuf. September 17, 2014.
• Mehr SR: The Continuing Evolution of Employer-Based Intervention in Diabetes Disease Management. Am J Manag Care (Evidence-Based Diabetes Care) http://www.ajmc.com/publications/evidence-based-diabetes-management/2014/march-2014/the-continuing-evolution-of-employer-based-intervention-in-diabetes-disease-management#sthash.EwU6IUe6.dpuf. March 17, 2014.
• Mehr SR, Zimmerman MP: What Is the Place of New SGLT-2 Inhibitors in Therapy and on the Formulary? Am J Manag Care (Evidence-Based Diabetes Care) http://www.ajmc.com/publications/evidence-based-diabetes-management/2014/march-2014/What-Is-the-Place-of-New-SGLT-2-Inhibitors-in-Therapy-and-on-the-Formulary#sthash.PwBmRMxK.dpuf. March 17, 2014.
• Mehr SR: Managing the Transition to Adulthood With Type 1 Diabetes Mellitus; An Interview With Robert Kritzler, MD, Pediatric Endocrinologist, and Deputy Chief Medical Officer, Johns Hopkins Health Care LLC. Am J Manag Care (Evidence-Based Diabetes Care) www.ajmc.com/publications/evidence-based-diabetes-management/2014/March-2014#sthash.Xrf6uJoz.dpuf . March 17, 2014.
• Mehr SR: The Link Between a Common Type of Bariatric Surgery and Increased Alcohol Use. Am J Manag Care (Evidence-Based Diabetes Care) http://www.ajmc.com/publications/evidence-based-diabetes-management/2014/March-2014#sthash.Xrf6uJoz.dpuf. March 17, 2014.
• Zimmerman MP, Mehr SR: Targeted Programmed Cell Death in Lung Cancer Treatment. Am J Manag Care (Evidence-Based Oncology) http://www.ajmc.com/publications/evidence-based-oncology/2014/march-2014/Targeted-Programmed-Cell-Death-in-Lung-Cancer-Treatment#sthash.Exivc1Py.dpuf. March 17, 2014.
• Mehr SR: The How and Why of Stress, Diabetes, and the Brain. Evidence-Based Diabetes Management May 2014.
• Mehr SR: Inhaled Insulin’s Long Journey to Commercialization. Evidence-Based Diabetes Management May 2014.
• Mehr SR: Ventilator-Acquired Pneumonia: The Question of Diagnosis in the Era of Accountable Care. Evidence-Based Respiratory Care Dec 2013.
• Mehr SR: Another Battle on the Adherence Front: How Rising Asthma Inhaler Prices Affect Payers. Evidence-Based Respiratory Care Dec 2013.
• Mehr SR, Zimmerman MP: The Keys to Obtaining Best Value in Non–Small Cell Lung Cancer. Evidence-Based Oncology 2012;1(3).
• Mehr SR: How Can We Get Better Value in End-of-Life Care? Evidence-Based Oncology 2012;1(3).
• FMCP Leadership Meeting: Improving Patient Care Through Research, Practice, and Leadership: Symposium Meeting Proceedings. Foundation for Managed Care Pharmacy and the Academy of Managed Care Pharmacy, Alexandria, Virginia, August 2012 (writing, edit, design)
• FMCP Research Symposium Meeting Proceedings. Foundation for Managed Care Pharmacy and the Academy of Managed Care Pharmacy, Alexandria, Virginia, March 2012 (writing, edit, design)
• Proceedings From the Inaugural Internship Strategic Steering Council (ISSC) Meeting. Foundation for Managed Care Pharmacy, Alexandria, Virginia, April 2012. (edit and design only)
• Mehr SM (ed): The Biotechnology Monitor and Survey. Wayne, New Jersey, Emron, Inc, 2008.
• Mehr SM (ed): The Biotechnology Monitor and Survey. Wayne, New Jersey, Emron, Inc, 2009. http://www.biotechmonitor.com/
• Managed Care and Reimbursement; International Oncology Research; Clinical Trials: Three monthly columns collated and edited by SM Health Communications LLC in Oncology and Biotech News.
• Value-Based Health Care: The Role of Pharmaceuticals, 2009: Proceedings of a Strategic Conference. Foundation for Managed Care Pharmacy, Alexandria, Virginia.